Comprehensive molecular characterization of Rho GTPases and their regulators across human cancers
International Journal of Cancer · 2025
DOI: 10.1002/ijc.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Shangyi Luo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Institute for Medical Engineering, Fuzhou University, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: rho GTP-Binding Proteins, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hong Kong Scholars Program, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Although defects in Rho GTPases have been implicated in cancer, a systematic assessment of the alterations in Rho GTPases and their regulators that facilitate conformational cycling between the active GTP‐bound and inactive GDP‐bound Rho GTPases is lacking across human cancers. Here, we depicted a comprehensive molecular characterization of 169 genes encoding Rho GTPases and their regulators, utilizing multi‐omics data of 9125 tumor samples across 33 cancer types from The Cancer Genome Atlas. Relevant findings were consolidated using mRNA expression profiles from 10,107 samples spanning seven distinct cancer types, along with data from multiple hepatocellular carcinoma (HCC) cohorts comprising 673 patients. We identified 19 candidate driver genes characterized by significant non‐silent somatic mutation patterns. Rho GTPase and its regulator genes exhibited widespread dysregulation across various cancer types, mediated by diverse mechanisms, including miRNA regulation, methylation patterns, and copy number alterations, which was significantly associated with patient overall survival. Notably, we found SYDE2 was significantly associated with poorer survival outcomes in KIRC, negatively regulated by miRNA‐142‐5p, with both exhibiting significant differential expression. Unsupervised consensus clustering was performed to identify common Rho GTPase regulation subtypes across human cancers; six subtypes were identified, with each exhibiting different associations with patient outcomes. Using HCC as an example, we found Cluster 6‐like tumors consistently exhibited aggressive characteristics, characterized by mutated TP53 and abnormal energy metabolism. Our study underscores the importance of Rho GTPases and their regulators in cancer development and establishes a foundation for the development of therapeutic targets based on Rho GTPase signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Institute for Medical Engineering, Fuzhou University, Fuzhou, Fujian, China.
- Department of Child and Adolescent Health, Public Health College, Harbin Medical University, Harbin, Heilongjiang, China.
- Heilongjiang Province Key Laboratory of Child Development and Genetic Research, Harbin Medical University, Harbin, Heilongjiang, China.
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, Heilongjiang, China.
ORCID-Profile: Yajing Zhang
Förderung
- National Natural Science Foundation of China
- Hong Kong Scholars Program
- China Postdoctoral Science Foundation
- Heilongjiang Postdoctoral Young Talents Program
- Fuzhou University Research Start-up Fund
- Tou-Yan Innovation Team Program of the Heilongjiang Province
Zitieren
APA
Luo, S., Qiao, S., Liu, L., Jia, Y., Zhang, Y., & Zhang, X. (2025). Comprehensive molecular characterization of Rho GTPases and their regulators across human cancers. International Journal of Cancer. https://doi.org/10.1002/ijc.70077
Vancouver
Luo S, Qiao S, Liu L, Jia Y, Zhang Y, Zhang X. Comprehensive molecular characterization of Rho GTPases and their regulators across human cancers. International Journal of Cancer. 2025. doi:10.1002/ijc.70077
BibTeX
@article{Luo2025,
author = {Luo, Shangyi and Qiao, Shupei and Liu, Li and Jia, Ying and Zhang, Yajing and Zhang, Xue},
title = {Comprehensive molecular characterization of Rho GTPases and their regulators across human cancers},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.70077}
}
EUVIMED